Clinical Trial Update: Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of RV1162 in healthy volunteers and COPD patients, with study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• RV1162

Snippet

Sponsor: Respivert Ltd | Conditions: Chronic Obstructive Pulmonary Disease (COPD), Healthy Volunteers | Phase 1 | Status: COMPLETED